

DEPARTMENT OF COMMERCE

Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

	APPLICATION NO. FILING DATE		FIRST NAMED INV	FIRST NAMED INVENTOR		ATTORNEY DOCKET NO.
	09/552,48	5 04/18/	00 SINGER		С	1662/49502
Г	026646 KENYON & KENYON			一	EXAMINER	
•			HM12/0823		HABTE	Ξ.Κ
	ONE BROAD				ART UNIT	PAPER NUMBER
	NEW YORK	NY 10004			1624 DATE MAILED:	9 08/23/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

	Application No.	Applicant(s)				
•	09/552,485	SINGER ET AL.				
Office Action Summary	Examiner	Art Unit				
	Kahsay Habte, Ph.					
The MAILING DATE of this communication app Period for Reply	pears on the cover sh	eet with the correspondence address				
A SHORTENED STATUTORY. PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1. after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period of - Failure to reply within the set or extended period for reply will, by statute - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	36(a). In no event, however, y within the statutory minimum will expire SIX of a cause the application to be	may a reply be timely filed n of thirty (30) days will be considered timely. (6) MONTHS from the mailing date of this communication.				
1) Responsive to communication(s) filed on						
_	— is action is non-final					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims	•					
4)⊠ Claim(s) <u>29-45</u> is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.		•••				
6)⊠ Claim(s) <u>29-45</u> is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or	r election requireme	nt				
Application Papers	·					
9) The specification is objected to by the Examine	r.					
10) The drawing(s) filed on is/are: a) accep		o by the Examiner				
Applicant may not request that any objection to the						
11)☐ The proposed drawing correction filed on		• •				
If approved, corrected drawings are required in rep						
12) The oath or declaration is objected to by the Exa	-					
Priority under 35 U.S.C. §§ 119 and 120		. :				
13) Acknowledgment is made of a claim for foreign	priority under 35 U.	S.C. § 119(a)-(d) or (f)				
a) ☐ All b) ☐ Some * c) ☐ None of:	, , , , , , , , , , , , , , , , , , , ,					
1. Certified copies of the priority documents	s have been receive	d.				
2. Certified copies of the priority documents						
Copies of the certified copies of the prior application from the International Bur See the attached detailed Office action for a list of the prior application from the prior application from the list of the prior application from the	ity documents have reau (PCT Rule 17.2	been received in this National Stage				
14) Acknowledgment is made of a claim for domestic						
a) The translation of the foreign language pro		· · · · · · · · · · · · · · · · · · ·				
15) Acknowledgment is made of a claim for domesti	c priority under 35 U	S.C. §§ 120 and/or 121.				
Attachment(s)	•					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 4	5) Not	erview Summary (PTO-413) Paper No(s) ice of Informal Patent Application (PTO-152) er:				
6. Patent and Trademark Office						

Application/Control Number: 09/552,485

Art Unit: 1624

DETAILED ACTION

Claim Rejections - 35 USC § 103

- 1. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
 - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claim Rejections - 35 USC § 102

2. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- (e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

Claims 44 and 45 are rejected under 35 U.S.C. 102(b) as anticipated by van der Burg et al (US Pat. No. 4,062,848) or, in the alternative, under 35 U.S.C. 103(a) as obvious over van der Burg'848. Claims 44 and 45 are rejected under 35 U.S.C. 102(b) as being anticipated by Van der Burg et al (US Pat. No. 4,062,848). Van der Burg et al. teaches the pharmaceutical formulation of mirtazapine compounds on column 1 (line 7).

Application/Control Number: 09/552,485

Art Unit: 1624

Water solutions are one of the known formulations for pharmaceutical composition.

Applicants claim pharmaceutical compositions of mirtazapine adduct that is the same as Van der Burg et al. Since an adduct of mirtazapine in aqueous solution is a pharmaceutical composition and would no longer be a water adduct of mirtazapine, the same material is obtained.

Claims 44 and 45 are alternatively rejected under 35 U.S.C. 103(a) as obvious over van der Burg'848. The cited reference teaches a pharmaceutical formulations on column 1 (line 7). Applicants claim in the instant application a water adduct of mirtazapine (a mixture of water and mirtazapine). Since water is one of the known compounds used as a pharmaceutical carrier, it would have been obvious at the time of the invention is was made to the person having ordinary skill in the art to select water as a carrier to make pharmaceutical composition.

2. Claims 44 and 45 are rejected under 35 U.S.C. 102(e) as being anticipated by Nickolson et al. (US Pat. No. 5,977,099). Nickolson et al. recites in claim 1 (column 6, lines 9-11) "a combination comprising mirtazapine or a pharmaceutical acceptable salt thereof and at least on SSRI's or a pharmaceutically acceptable salt" that is embraced by the rejected claims. In the instant application, there has been recited in claim 44 "a pharmaceutical composition comprising a therapeutically effective amount" that is an open-end language. The phrase "comprising" is an open claim language and reads on all possible combination or composition of mirtazapine with other ingredients. Since

Page 3

Application/Control Number: 09/552,485

Art Unit: 1624

applicant's pharmaceutical composition of mirtazapine compounds are the same as Nickolson et al., a 102(e) rejection is proper. Note previous rejection.

3. Claims 29-43 are rejected under 35 U.S.C. 102(b) as being unpatentable over Kaspersen *et al.* Kaspersen *et al.* on page 1066 teaches crystallization of mirtazapine crude product from methanol/water to achieve colorless crystals. In claims 29-43, there has been recited an adduct of mirtazapine and the method of its preparation (precipitation from organic solvents such as alcohols). It appears to be the same process and therefore the products are presumed to be the same, i.e. inherently formed. See In re Zelinski 141 USPQ 217, In re Best 195 USPQ 432, and In re Wiegand 86 USPQ 155. Applicants can overcome the rejection over Kaspersen *et al.* by showing that their product is different from Kaspersen *et al.*, e.g. different melting point.

Claim Rejections - 35 USC § 112

4. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 36 and 42 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claims 36 and 42 recite "the adduct of mirtazapine and water ... containing up to about three weight percent water", but the said claims

Page 5

appear to be duplicates of claim 30. Whether a compound is precipitated from alcohol or any organic solvent, the final product is the same, as this is the only way to prepare.

Conclusion

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kahsay Habte, Ph. D. whose telephone number is (703) 308-4717. The examiner can normally be reached on M-F (9.00AM- 5:30PM).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mukund Shah can be reached on 703-308-4716. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

Af KahSay Mabk Kahsay Habte, Ph. D.

Examiner Art Unit 1624 Mark L. Berch
Primary Examiner
Art Unit 1624

KH

August 17, 2001